risk of thromboembolic event – MD Update

Special Section

In the Pursuit of Prevention

August 1, 2013 Jennifer S. Newton amount of alcohol consumption, avenue of early detection, BCPT, benefit prior, board-certified, BRCA, BRCA1, BRCA2, breast, breast cancer, breast cancer care, breast cancer prevention trial, breast tissue, cancer, cancer center, chemoprevention, chemoprevention drug, chemoprevention medication, detection, develop breast cancer, early detection, early study of a chemoprevention drug, effect of endogenous estrogen, endogenous estrogen, equivalent success rate, estrogen, estrogen receptor, Evista®, exemestane, family history, FDA, Floyd, Floyd memorial, Floyd memorial 's cancer center, Floyd memorial 's cancer center of Indiana, genetic test, giant stride, hematologist, high risk, Ifeoma Roseline Okeke, increase risk of endometrial cancer, Indiana, lifetime risk, majority of adult woman, mammogram, mammography, mastectomy, medical oncologist, metastatic set, modern mammography, multiple trial, mutation, Okeke, Okeke turn, oncologist, ovarian cancer, physician, positive breast cancer, post-menopausal, post-menopausal woman, prevent breast cancer, prevent estrogen receptor, prevention, prophylactic mastectomy, prophylactic surgery, pursuit of prevention, Raloxifene, receptor, risk of thromboembolic event, screen staple, side effect of chemoprevention medication, Star researcher, Star trial, study of Tamoxifen, success rate, successful effective rate, tamoxifen, thromboembolic event

NEW ALBANY, IN Mention the word “mammogram,” and some women might cringe at the discomfort the test can cause. But

Read more